同步寡转移非小细胞肺癌的定义:一项系统综述
该系统综述检索MEDLINE并分析21篇涉及同步寡转移非小细胞肺癌定义的文章,发现81%的研究要求脑磁共振或CT、胸腹部CT及PET分期,转移灶总数上限1至8个不等、38.1%研究定为5个,多数未定义累及器官数或单器官转移上限,仅27.8%将纵隔淋巴结计入转移部位;未获得统一、公认的定义。
要点
- 21篇文献中81%要求脑MRI或CT、胸腹部CT及PET进行扩展分期。
- 转移灶总数上限1至8个不等,38.1%的研究定为最多5个。
- 仅27.8%文献将纵隔淋巴结受累计为转移部位,多数未定义器官数或单器官转移上限。
核心结论
- 本系统综述未检索到同步寡转移非小细胞肺癌的统一、公认定义。
- 多数研究要求进行扩展分期,作者认为公认的肿瘤学同步寡转移定义对筛选患者以设计前瞻性临床试验至关重要。
研究设计与样本
- 系统综述,按人群、干预、对照和结局策略构建一个研究问题,在MEDLINE(OvidSP)中检索。
- 纳入并分析所有涉及同步寡转移非小细胞肺癌且给出同步寡转移定义的文章,共检索到21篇符合条件的文章。
主要发现
- 17项研究(81%)要求患者接受脑磁共振成像或计算机断层扫描、胸部和腹部计算机断层扫描以及正电子发射断层扫描进行分期。
- 各定义允许的转移灶总数范围为1至8个,但38.1%的研究中最大数目为5个。
- 大多数出版物未定义受累器官数目或每个器官的最大转移灶数目。
- 关于纵隔淋巴结受累,仅5篇文章(27.8%)将其计为转移部位。
关键数值与推荐
- 17项研究(81%)要求脑磁共振成像或计算机断层扫描、胸部和腹部计算机断层扫描以及正电子发射断层扫描分期。
- 转移灶总数上限范围为1至8个,38.1%的研究定为最多5个。
- 仅5篇文章(27.8%)将纵隔淋巴结受累计为转移部位。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Synchronous oligometastatic (sOM) disease is an oncological concept characterized by a limited cancer burden. Patients with oligometastasis could potentially benefit from local radical treatments. Despite the fact that the sOM condition is well recognized, a universal definition, including a specific definition for NSCLC, is not yet available. The aim of this systematic review was to summarize the definitions of and staging requirements for use of the term synchronous oligometastatic in the context of NSCLC. METHODS: The key issue was formulated in one research question according to the population, intervention, comparator, and outcomes strategy. The question was introduced in MEDLINE (OvidSP). All articles dealing with sOM NSCLC and providing a definition of synchronous oligometastasis in NSCLC were selected and analyzed. RESULTS: A total of 21 eligible articles focusing on sOM NSCLC were retrieved and analyzed. In 17 studies (81%), patients had to be staged with magnetic resonance imaging or computed tomography of the brain, thoracic and abdominal computed tomography, and positron emission tomography. The total number of metastases allowed in the definitions ranged from one to eight, but in 38.1% of studies the maximum number was 5. Most of the publications did not define the number of involved organs or the maximum number of metastases per organ. For mediastinal lymph node involvement, only five articles (27.8%) counted this as a metastatic site. CONCLUSIONS: No uniform definition of sOM NSCLC could be retrieved by this systematic review. However, extended staging was mandated in most of the studies. An accepted oncological definition of synchronous oligometastasis is essential for patient selection to define prospective clinical trials.
引用
- Giaj-Levra N, Giaj-Levra M, Durieux V, et al. Defining Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Systematic Review. J Thorac Oncol. 2019. PMID: 31195177. doi:10.1016/j.jtho.2019.05.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。